WO2007089335A3 - Multicyclic amino acid derivatives and methods of their use - Google Patents
Multicyclic amino acid derivatives and methods of their use Download PDFInfo
- Publication number
- WO2007089335A3 WO2007089335A3 PCT/US2006/047579 US2006047579W WO2007089335A3 WO 2007089335 A3 WO2007089335 A3 WO 2007089335A3 US 2006047579 W US2006047579 W US 2006047579W WO 2007089335 A3 WO2007089335 A3 WO 2007089335A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- amino acid
- acid derivatives
- multicyclic
- multicyclic amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0620756-1A BRPI0620756B1 (en) | 2005-12-29 | 2006-12-12 | MULTICYCLIC AMINO ACID DERIVATIVES, PHARMACEUTICAL FORMULATION INCLUDING THE SAME AND THEIR USES TO INHIBIT THE ACTIVITY OF TRYPTOPHAN HYDROXYLASE 1 (TPH1) |
CA2635531A CA2635531C (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
PL06849951T PL1984344T3 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
KR1020087015697A KR101360621B1 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
JP2008548561A JP5483883B2 (en) | 2005-12-29 | 2006-12-12 | Polycyclic amino acid derivatives and methods of use thereof |
NZ568946A NZ568946A (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
ES06849951T ES2395392T3 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
EP06849951A EP1984344B1 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
DK06849951.6T DK1984344T3 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods for their use |
EA200870127A EA019879B1 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives, pharmaceutical composition containing them and method of treatment using these derivatives |
CN2006800499070A CN101351451B (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
AU2006337137A AU2006337137B2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
IL191998A IL191998A (en) | 2005-12-29 | 2008-06-05 | Compounds and pharmaceutical formulations of multicyclic amino acid derivatives and their use |
NO20083324A NO344848B1 (en) | 2005-12-29 | 2008-07-28 | Multicyclic amino acid derivatives and methods for their use |
HK09102308.4A HK1124841A1 (en) | 2005-12-29 | 2009-03-11 | Multicyclic amino acid derivatives and methods of their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75495505P | 2005-12-29 | 2005-12-29 | |
US60/754,955 | 2005-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007089335A2 WO2007089335A2 (en) | 2007-08-09 |
WO2007089335A3 true WO2007089335A3 (en) | 2007-10-11 |
Family
ID=38327831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/047579 WO2007089335A2 (en) | 2005-12-29 | 2006-12-12 | Multicyclic amino acid derivatives and methods of their use |
Country Status (21)
Country | Link |
---|---|
US (3) | US7723345B2 (en) |
EP (2) | EP2386547B1 (en) |
JP (1) | JP5483883B2 (en) |
KR (1) | KR101360621B1 (en) |
CN (2) | CN103265495B (en) |
AU (1) | AU2006337137B2 (en) |
BR (1) | BRPI0620756B1 (en) |
CA (1) | CA2635531C (en) |
DK (1) | DK1984344T3 (en) |
EA (1) | EA019879B1 (en) |
EC (1) | ECSP088590A (en) |
ES (2) | ES2395392T3 (en) |
HK (1) | HK1124841A1 (en) |
IL (1) | IL191998A (en) |
NO (1) | NO344848B1 (en) |
NZ (1) | NZ568946A (en) |
PL (1) | PL1984344T3 (en) |
PT (1) | PT1984344E (en) |
UA (1) | UA96936C2 (en) |
WO (1) | WO2007089335A2 (en) |
ZA (1) | ZA200805192B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362248B2 (en) | 2005-01-10 | 2013-01-29 | Arena Pharmaceuticals, Inc. | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
US8410119B2 (en) | 2003-07-14 | 2013-04-02 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US8546429B2 (en) | 2003-07-11 | 2013-10-01 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1848435B1 (en) | 2005-01-25 | 2016-01-20 | Synta Pharmaceuticals Corp. | Compounds against inflammations and immune-related uses |
ES2395392T3 (en) * | 2005-12-29 | 2013-02-12 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
US7855291B2 (en) * | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
SI2848610T1 (en) * | 2006-11-15 | 2018-02-28 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
GB0705400D0 (en) * | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
CN101969952A (en) * | 2007-06-26 | 2011-02-09 | 莱西肯医药有限公司 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
EP2170306A1 (en) * | 2007-06-26 | 2010-04-07 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
AU2008275179B2 (en) | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
WO2009014972A1 (en) * | 2007-07-26 | 2009-01-29 | Lexicon Pharmaceuticals, Inc. | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
EP2529740A1 (en) * | 2007-08-24 | 2012-12-05 | Lexicon Pharmaceuticals, Inc. | Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds. |
TWI439457B (en) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
US20100260772A1 (en) * | 2007-09-28 | 2010-10-14 | The Trustees Of Columbia University In The City Of New York | Methods for treating or preventing diseases associated with low bone mass |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
MX2010008376A (en) * | 2008-02-04 | 2011-02-22 | Mercury Therapeutics Inc | Ampk modulators. |
AU2009231892A1 (en) * | 2008-03-31 | 2009-10-08 | The Trustees Of Columbia University In The City Of New York | Methods of diagnosing, preventing and treating bone mass diseases |
US20100022549A1 (en) * | 2008-07-23 | 2010-01-28 | The Scripps Research Institute | Alpha-helix mimetic with functionalized pyridazine |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
AU2009298419A1 (en) * | 2008-10-03 | 2010-04-08 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors and methods of their use |
KR20110074875A (en) * | 2008-10-24 | 2011-07-04 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Process for the preparation of substituted phenylalanines |
WO2010062829A1 (en) * | 2008-11-28 | 2010-06-03 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for treating osteoporosis |
WO2010065333A1 (en) * | 2008-12-01 | 2010-06-10 | Lexicon Pharmaceuticals, Inc. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis |
WO2011053977A1 (en) * | 2009-11-02 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
CN102711749A (en) * | 2009-11-05 | 2012-10-03 | 莱西肯医药有限公司 | Tryptophan hydroxylase inhibitors for the treatment of cancer |
AU2010321979A1 (en) | 2009-11-19 | 2012-05-24 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
EP2504008A1 (en) * | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
US20120077831A1 (en) * | 2009-11-23 | 2012-03-29 | Philip Manton Brown | Methods and assays for the treatment of irritable bowel syndrome |
WO2011100285A1 (en) | 2010-02-10 | 2011-08-18 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease |
TWI513694B (en) | 2010-05-11 | 2015-12-21 | Amgen Inc | Pyrimidine compounds that inhibit anaplastic lymphoma kinase |
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
TW201245183A (en) * | 2010-11-05 | 2012-11-16 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid |
GB201203793D0 (en) * | 2012-03-05 | 2012-04-18 | Ge Healthcare Ltd | Imaging neural activity |
US20130303763A1 (en) | 2012-03-30 | 2013-11-14 | Michael D. Gershon | Methods and compositions for the treatment of necrotizing enterocolitis |
WO2014195847A2 (en) | 2013-06-03 | 2014-12-11 | Actelion Pharmaceuticals Ltd | Novel use of stable isotope labeled l-tryptophan |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
UA119247C2 (en) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
CA2927121A1 (en) * | 2013-11-19 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase |
AR098436A1 (en) | 2013-11-19 | 2016-05-26 | Actelion Pharmaceuticals Ltd | TRIPYCLIC COMPOUNDS OF PIPERIDINE |
WO2015089137A1 (en) * | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
JPWO2015163435A1 (en) | 2014-04-24 | 2017-04-20 | 田辺三菱製薬株式会社 | Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and their pharmaceutical use |
WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
HUE057569T2 (en) | 2014-12-17 | 2022-05-28 | Pimco 2664 Ltd | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
WO2016109501A1 (en) * | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
JP2016204314A (en) * | 2015-04-23 | 2016-12-08 | 国立研究開発法人理化学研究所 | Compound and method for producing 4-boronophenylalanine derivative |
WO2016177690A1 (en) | 2015-05-04 | 2016-11-10 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
BR112017027656B1 (en) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF |
JP2020507611A (en) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Compounds and methods for the treatment of primary biliary cholangitis |
EP3674303B1 (en) * | 2017-08-24 | 2022-07-20 | Gwangju Institute of Science and Technology | Novel tryptophan hydroxylase inhibitor and pharmaceutical composition including same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035864A1 (en) * | 1998-12-16 | 2000-06-22 | Bayer Aktiengesellschaft | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
WO2002018320A2 (en) * | 2000-08-31 | 2002-03-07 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
US20040082496A1 (en) * | 1999-04-30 | 2004-04-29 | Acton Susan L. | ACE-2 modulating compounds and methods of use thereof |
WO2005112906A2 (en) * | 2004-05-21 | 2005-12-01 | Duke University | Method for augmenting the effects of serotonin reuptake inhibitors |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH471146A (en) | 1966-03-16 | 1969-04-15 | Geigy Ag J R | Process for the preparation of new morpholine derivatives |
US4866181A (en) * | 1986-08-29 | 1989-09-12 | Aldrich-Boranes, Inc. | Process for producing optically active alcohols |
US4916074A (en) * | 1986-10-30 | 1990-04-10 | Chisso Corporation | Process for producing optically active compounds |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
ATE168671T1 (en) * | 1991-03-21 | 1998-08-15 | Solutia Europ Nv Sa | IMPROVED CATALYTIC PROCESS FOR THE SELECTIVE ALKYLATION OF AROMATIC HYDROCARBONS |
DE4131924A1 (en) * | 1991-09-25 | 1993-07-08 | Hoechst Ag | SUBSTITUTED 4-ALKOXYPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL |
NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
HUT74690A (en) | 1993-11-24 | 1997-01-28 | Du Pont Merck Pharma | Novel isoxazoline and isoxazole fibrinogen receptor antagonists process for producing them and pharmaceutical compositions containing them |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
GB9518553D0 (en) | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
PT796855E (en) | 1996-03-20 | 2002-07-31 | Hoechst Ag | INHIBITION OF REABSORCAO IN BONES AND ANTAGONISTS OF VITRONECTIN |
US5958957A (en) * | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
JP4180790B2 (en) | 1997-08-20 | 2008-11-12 | 協和メデックス株式会社 | Novel substance 2-amino-3- [2- (α-mannopyranosyl) indol-3-yl] propionic acid, a method for producing the same, and a method for examining biological functions using the novel substance |
US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
US6229011B1 (en) * | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
JP2002507562A (en) * | 1998-03-27 | 2002-03-12 | ファルマシア・アンド・アップジョン・カンパニー | Use of cabergoline in the treatment of restless leg syndrome |
US6423727B1 (en) * | 1998-04-23 | 2002-07-23 | Novartis Ag | Certain thiol inhibitors of endothelin-converting enzyme |
WO2000019994A1 (en) | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
JP2000204085A (en) | 1998-11-13 | 2000-07-25 | Nippon Bayer Agrochem Co Ltd | Isothiazole carboxylic acid derivative and disease controlling agent |
US6677360B2 (en) * | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
IL144636A0 (en) | 1999-02-18 | 2002-05-23 | Hoffmann La Roche | Thioamide derivatives |
US7125883B1 (en) | 1999-04-13 | 2006-10-24 | Abbott Gmbh & Co. Kg | Integrin receptor ligands |
ATE271922T1 (en) | 1999-06-01 | 2004-08-15 | Elan Pharma Int Ltd | SMALL MILL AND METHOD THEREOF |
EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
JP3795305B2 (en) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | Pharmaceutical composition |
AU6903200A (en) | 1999-08-16 | 2001-03-13 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
WO2001021584A1 (en) * | 1999-09-24 | 2001-03-29 | Genentech, Inc. | Tyrosine derivatives |
DE10028575A1 (en) | 2000-06-14 | 2002-03-14 | Basf Ag | integrin |
CA2386457A1 (en) * | 1999-10-06 | 2001-04-12 | Basf Aktiengesellschaft | Inhibitors of the endothelin signalling pathway and .alpha.v.beta.3 integrin receptor antagonists for combination therapy |
WO2001030333A2 (en) * | 1999-10-27 | 2001-05-03 | Sunol Molecular Corporation | Tissue factor antagonists and methods of use thereof |
WO2001036376A1 (en) * | 1999-11-18 | 2001-05-25 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
US6388084B1 (en) * | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
WO2001051487A1 (en) * | 1999-12-28 | 2001-07-19 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
AU3693200A (en) | 2000-01-26 | 2001-08-07 | Kansas State University Research Foundation | Preparation and use of polymers crosslinked with tyrosine-containing peptides |
FR2804427B1 (en) * | 2000-01-27 | 2002-09-06 | Rhodia Chimie Sa | PROCESS FOR THE PREPARATION OF ALPHA-HALOGENATED KETONES |
WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
NZ523428A (en) * | 2000-06-28 | 2008-03-28 | Prana Biotechnology Ltd | Neurotoxic oligomers |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6689781B2 (en) * | 2000-07-21 | 2004-02-10 | Elan Pharmaceuticals, Inc. | Phenylalanine derivatives as alpha 4 integrin inhibitors |
US7015216B2 (en) * | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
DE60143984D1 (en) | 2000-08-18 | 2011-03-17 | Ajinomoto Kk | NEW PHENYLALANINE DERIVATIVES |
DE10042655A1 (en) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Process for the preparation of inhibitors of cell adhesion |
AU2001290303A1 (en) * | 2000-09-29 | 2002-04-15 | Ajinomoto Co., Inc. | Novel phenylalanine derivatives |
DE10112768A1 (en) * | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | New heterocyclic-substituted phenyl compounds, are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, restenosis or tumor diseases |
DE60236418D1 (en) * | 2001-03-19 | 2010-07-01 | Dainippon Sumitomo Pharma Co | ARYLSUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION CONTAINING THEREOF |
WO2002081467A1 (en) | 2001-04-09 | 2002-10-17 | Ortho-Mcneil Pharmaceutical, Inc. | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
US6867025B2 (en) * | 2001-05-29 | 2005-03-15 | Lexicon Genetics Incorporated | Human hydroxylases and polynucleotides encoding the same |
US6976647B2 (en) | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
WO2002098565A1 (en) | 2001-06-05 | 2002-12-12 | Elan Pharma International Limited | System and method for milling materials |
US6951840B2 (en) * | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
EP1454898A4 (en) * | 2001-12-13 | 2006-12-13 | Ajinomoto Kk | Novel phenylalanine derivative |
US20030171368A1 (en) * | 2002-02-06 | 2003-09-11 | Werner Seitz | Pyrimidinonesulfamoylureas` |
WO2003070709A1 (en) * | 2002-02-20 | 2003-08-28 | Ajinomoto Co.,Inc. | Novel phenylalanine derivative |
JP2005535568A (en) * | 2002-04-03 | 2005-11-24 | ノバルティス アクチエンゲゼルシャフト | 5-Substituted 1,1-dioxo-'1,2,5 as PTPase inhibitor! Thiazolidin-3-one derivative |
WO2003089410A1 (en) | 2002-04-19 | 2003-10-30 | Kyowa Hakko Kogyo Co., Ltd. | Phenylalanine derivative |
AU2003232941A1 (en) | 2002-06-07 | 2003-12-22 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
GB0213122D0 (en) | 2002-06-07 | 2002-07-17 | Glaxo Group Ltd | Compounds |
DE10226921A1 (en) * | 2002-06-17 | 2003-12-24 | Bayer Ag | Antibacterial amide macrocycles |
DE10234422A1 (en) * | 2002-07-29 | 2004-02-12 | Bayer Ag | Antibacterial ester macrocycles |
US7122580B2 (en) * | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
JPWO2004035522A1 (en) * | 2002-08-30 | 2006-02-16 | 株式会社 ビーエフ研究所 | Diagnostic probes and therapeutic agents for prion protein storage diseases and dyes for prion protein |
JP4878839B2 (en) | 2002-09-11 | 2012-02-15 | エラン ファーマ インターナショナル,リミティド | Gel-stabilized nanoparticle active substance composition |
WO2004043349A2 (en) | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
DE60330997D1 (en) | 2002-11-19 | 2010-03-04 | Galderma Res & Dev | BIAROMATIC COMPOUNDS ACTIVATE THE PPAR-GAMMA RECEPTORS AND THEIR APPLICATIONS IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS |
MXPA05006569A (en) * | 2002-12-20 | 2005-09-22 | Pharmacia Corp | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds. |
ITMI20022738A1 (en) | 2002-12-23 | 2004-06-24 | Zambon Spa | PHTHALAZINE DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4. |
ES2314271T3 (en) | 2002-12-24 | 2009-03-16 | Astrazeneca Ab | THERAPEUTIC QUINAZOLINE DERIVATIVES. |
JPWO2004080943A1 (en) * | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | Cinnamyl alcohol derivative compound and drug containing the compound as an active ingredient |
US20050234066A1 (en) * | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
US20050187266A1 (en) * | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
CN1720246A (en) | 2003-04-21 | 2006-01-11 | 捷克共和国乌斯塔夫化学与生物化学研究院 | (Purin-6-yl) amino acid and production method thereof |
WO2004110350A2 (en) * | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
CA2529154C (en) * | 2003-06-20 | 2013-05-07 | Galderma Research & Development, S.N.C. | Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions |
US20050042177A1 (en) | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
CN1832920A (en) | 2003-08-08 | 2006-09-13 | 特兰斯泰克制药公司 | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014532A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
JP2008502583A (en) | 2003-10-01 | 2008-01-31 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Antibacterial amide macrocycle |
US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
CA2543239A1 (en) * | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as ppar activators |
DE10358824A1 (en) * | 2003-12-16 | 2005-07-21 | Bayer Healthcare Ag | Antibacterial macrocycles with substituted biphenyl |
EP1700850B1 (en) * | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
WO2005069845A2 (en) | 2004-01-14 | 2005-08-04 | Ohio University | Methods of producing peptides/proteins in plants and peptides/proteins produced thereby |
JP2007126358A (en) | 2004-01-20 | 2007-05-24 | Fujiyakuhin Co Ltd | Phenylalanine derivative |
ES2541779T3 (en) | 2004-02-05 | 2015-07-24 | The Ohio State University Research Foundation | Chimeric VEGF Peptides |
MXPA06009100A (en) | 2004-02-10 | 2007-02-02 | Johnson & Johnson | Pyridazinones as antagonists of a4 integrins. |
EP1778214A4 (en) * | 2004-07-27 | 2010-04-14 | Glaxosmithkline Llc | Novel biphenyl compounds and their use |
WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
ES2395392T3 (en) * | 2005-12-29 | 2013-02-12 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
US7897763B2 (en) * | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
UA99270C2 (en) * | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
CN101969952A (en) * | 2007-06-26 | 2011-02-09 | 莱西肯医药有限公司 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
AU2008275179B2 (en) * | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
TWI439457B (en) * | 2007-09-28 | 2014-06-01 | Lexicon Pharmaceuticals Inc | Solid forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
-
2006
- 2006-12-12 ES ES06849951T patent/ES2395392T3/en active Active
- 2006-12-12 EP EP11005146.3A patent/EP2386547B1/en active Active
- 2006-12-12 DK DK06849951.6T patent/DK1984344T3/en active
- 2006-12-12 AU AU2006337137A patent/AU2006337137B2/en active Active
- 2006-12-12 KR KR1020087015697A patent/KR101360621B1/en active IP Right Grant
- 2006-12-12 BR BRPI0620756-1A patent/BRPI0620756B1/en active IP Right Grant
- 2006-12-12 US US11/638,677 patent/US7723345B2/en active Active
- 2006-12-12 CA CA2635531A patent/CA2635531C/en not_active Expired - Fee Related
- 2006-12-12 WO PCT/US2006/047579 patent/WO2007089335A2/en active Application Filing
- 2006-12-12 PL PL06849951T patent/PL1984344T3/en unknown
- 2006-12-12 CN CN201310082551.2A patent/CN103265495B/en active Active
- 2006-12-12 EA EA200870127A patent/EA019879B1/en not_active IP Right Cessation
- 2006-12-12 PT PT68499516T patent/PT1984344E/en unknown
- 2006-12-12 JP JP2008548561A patent/JP5483883B2/en active Active
- 2006-12-12 ZA ZA200805192A patent/ZA200805192B/en unknown
- 2006-12-12 NZ NZ568946A patent/NZ568946A/en unknown
- 2006-12-12 EP EP06849951A patent/EP1984344B1/en active Active
- 2006-12-12 CN CN2006800499070A patent/CN101351451B/en active Active
- 2006-12-12 UA UAA200809740A patent/UA96936C2/en unknown
- 2006-12-12 ES ES11005146.3T patent/ES2684821T3/en active Active
-
2008
- 2008-06-05 IL IL191998A patent/IL191998A/en active IP Right Grant
- 2008-06-30 EC EC2008008590A patent/ECSP088590A/en unknown
- 2008-07-28 NO NO20083324A patent/NO344848B1/en unknown
-
2009
- 2009-03-11 HK HK09102308.4A patent/HK1124841A1/en unknown
-
2010
- 2010-03-30 US US12/750,278 patent/US8063057B2/en active Active
-
2011
- 2011-11-07 US US13/290,261 patent/US8629156B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035864A1 (en) * | 1998-12-16 | 2000-06-22 | Bayer Aktiengesellschaft | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
US20040082496A1 (en) * | 1999-04-30 | 2004-04-29 | Acton Susan L. | ACE-2 modulating compounds and methods of use thereof |
WO2002018320A2 (en) * | 2000-08-31 | 2002-03-07 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
WO2005112906A2 (en) * | 2004-05-21 | 2005-12-01 | Duke University | Method for augmenting the effects of serotonin reuptake inhibitors |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US8546429B2 (en) | 2003-07-11 | 2013-10-01 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US8410119B2 (en) | 2003-07-14 | 2013-04-02 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US8362248B2 (en) | 2005-01-10 | 2013-01-29 | Arena Pharmaceuticals, Inc. | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007089335A3 (en) | Multicyclic amino acid derivatives and methods of their use | |
WO2008073933A3 (en) | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | |
WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
WO2008049116A3 (en) | Substituted indoles | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
WO2005103050A3 (en) | Azaindoles useful as inhibitors of rock and other protein kinases | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
WO2008030511A3 (en) | Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes | |
WO2007084391A3 (en) | Thiazole compounds as protein kinase b ( pkb) inhibitors | |
NO20065727L (en) | Pyrrole inhibitors of arch-protein kinase, their synthesis and their intermediates | |
NO20083501L (en) | Azaindoles useful as inhibitors of Janus kinases | |
WO2006086562A3 (en) | Phenylazetidinone derivatives | |
WO2007075895A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
NO20073140L (en) | Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases | |
WO2007022225A3 (en) | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof | |
WO2007050587A3 (en) | Therapeutic compositions and methods | |
NO20074431L (en) | Pyrrolopyrimidines useful as protein kinase inhibitors | |
WO2008076392A3 (en) | Compounds useful as protein kinase inhibitors | |
WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2004080964A8 (en) | Indole derivatives useful for the treatment of diseases | |
WO2008116139A3 (en) | N-heterocyclic compounds useful as inhibitors of janus kinases | |
WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
WO2010011772A3 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049907.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006337137 Country of ref document: AU Ref document number: 568946 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501522 Country of ref document: PH Ref document number: 5368/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2635531 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006337137 Country of ref document: AU Date of ref document: 20061212 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008548561 Country of ref document: JP Ref document number: 2008061101 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008483 Country of ref document: MX Ref document number: 1020087015697 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08074441 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870127 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006849951 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06849951 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: PI0620756 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |